Barrett carcinoma - Diagnosis, screening, surveillance, endoscopic treatment, prevention;Barrett-karzinom - Diagnose, screening, surveillance, endoskopische therapie, prävention

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 12, 2007, Pages 1264-1272

  Peitz, Ulrich ^a   Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Adenocarcinoma; Barrett's esophagus; Endoscopic resection; Screening; Surveillance

Indexed keywords

BARRETT CARCINOMA; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INFILTRATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; ENDOSCOPIC SURGERY; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; GOBLET CELL; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; LIFESTYLE; METASTASIS; MORBIDITY; OBESITY; REVIEW;

ADENOCARCINOMA; BARRETT ESOPHAGUS; EARLY DIAGNOSIS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; HUMANS; LYMPHATIC METASTASIS; MASS SCREENING; METAPLASIA; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 38349070305     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963638     Document Type: Review

References (127)

1. Schlansky B, Dimarino AJ Jr, Loren D et al. A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther 2006; 23 (5): 587-593
2. Barret NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 1950; 38 (150): 175-182
3. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97 (8): 1888-1895
4. Koop H, Schepp W, Muller-Lissner S et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol 2005; 43 (2): 163-164
5. Messmann H, Ell C, Fein M et al. Topic Complex VI: Barrett esophagus. Z Gastroenterol 2005; 43 (2): 184-190
6. Watson A, Heading RC, Shepherd NA. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. 2005. http://www.bsg.org.uk
7. Boyer J, Robaszkiewicz M. Guidelines of the French Society of Digestive Endoscopy: monitoring of Barrett's esophagus. The Council of the French Society of Digestive Endoscopy. Endoscopy 2000; 32 (6): 498-499
8. Chandrasoma PT, Der R, Ma Y et al. Histologic classification of patients based on mapping biopsies of the gastroesophageal junction. Am J Surg Pathol 2003; 27 (7): 929-936
9. Chandrasoma P. Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology 2005; 46 (4): 361-373
10. Peitz U, Vieth M, Pross M et al. Cardia-type metaplasia arising in the remnant esophagus after cardia resection. Gastrointest Endosc 2004; 59 (7): 810-817
11. Shaheen NJ, Crosby MA, Bozymski EM et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119 (2): 333-338
12. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma - a population-based cohort study. Am J Gastroenterol 2006; 101 (6): 1193-1199
13. Malfertheiner P, Peitz U. The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia. Gut 2005; 54 Suppl 1:i13-i20
14. Anandasabapathy S, Jhamb J, Davila M et al. Clinical and endoscopic factors predict higher pathologic gtades of Barrett dysplasia. Cancer 2007; 109 (4): 668-674
15. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131 (5): 1392-1399
16. Theisen J, Stein HJ, Dittler HJ et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc 2002; 16 (4): 671-673
17. Hamilton R, Aaltonen LA. Tumors of the gastrointestinal system; WHO classification. Lyon: IARC Press, 2000
18. von Rahden BH, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol 2006; 12 (41): 6608-6613
19. Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47 (2): 251-255
20. Bollschweiler E, Wolfgarten E, Gutschow C et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92 (3): 549-555
21. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83 (10): 2049-2053
22. Bytzer P, Christensen PB, Damkier P et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94 (1): 86-91
23. Corley DA, Buffer PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001; 30 (6): 1415-1425
24. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst 2004; 96 (18): 1383-1387
25. Nguyen AM, Luke CG, Roder D. Comparative epidemiological characteristics of oesophageal adenocarcinoma and other cancers of the oesophagus and gastric cardia. Asian Pac J Cancer Prev 2003; 4 (3): 225-231
26. Bareiss D, Stabenow R, Muller R et al. (Current epidemiology of carcinoma of the esophagus and cardia in Germany]. Dtsch Med Wochenschr 2002; 127 (25-26): 1367-1374
27. Chow WH, Blot WJ, Vaughan TL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90 (2): 150-155
28. de Jonge PJ, Steyerberg EW, Kuipers EJ et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006; 101 (7): 1421-1429
29. Guardino JM, Khandwala F, Lopez R et al. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006; 101 (10): 2187-2193
30. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130 (11): 883-890
31. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340 (11): 825-831
32. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001; 12 (8): 721-732
33. El Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43 (3): 327-333
34. Kendall BJ, Whiteman DC. Temporal changes in the endoscopic frequency of new cases of Barrett's esophagus in an Australian health region. Am J Gastroenterol 2006; 101 (6): 1178-1182
35. Conio M, Cameron AJ, Romero Y et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001; 48 (3): 304-309
36. Hurschler D, Borovicka J, Neuweiler J et al. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. Swiss Med Wkly 2003; 133 (37-38): 507-514
37. Prach AT, MacDonald TA, Hopwood DA et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997; 350 (9082): 933
38. van Soest EM, Dieleman JP, Siersema PD et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54 (8): 1062-1066
39. Hagen JA, DeMeester SR, Peters JH et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001; 234 (4): 520-530
40. Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 2004; 99 (3): 419-424
41. Victorzon M, Tolonen P, Kohonen M et al. Outcome of surgery for oesophageal carcinoma in a low volume centre, with and without preoperative chemoradiotherapy. Scand J Surg 2004; 93 (1): 37-42
42. Van Veldhuyzen Zanten SJ, Thomson AB, Barkun AN et al. The prevalence of Barrett's oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. Aliment Pharmacol Ther 2006; 23 (5): 595-599
43. Solaymani-Dodaran M, Logan RF, West J et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53 (8): 1070-1074
44. Solaymani-Dodaran M, Logan RF, West J et al. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses - a population-based cohort study. Am J Gastroenterol 2005; 100 (12): 2616-2621
45. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122 (2): 588-590
46. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment Pharmacol Ther 2004; 20 Suppl 5: 40-47
47. Hanna S, Rastogi A, Weston AP et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006; 101 (7): 1416-1420
48. Sharma P, Weston AP, Topalovski M et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003; 52 (1): 24-27
49. Kiesslich R, Neurath MF, Galle PR. Chromoendoscopy and magnifying endoscopy in patients with gastroesophageal reflux disease. Useful or negligible? Dig Dis 2004; 22 (2): 142-147
50. Kiesslich R, von Bergh M, Hahn M et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33 (12): 1001-1006
51. Kiesslich R, Hahn M, Herrmann G et al. Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett's esophagus and a normal control group. Gastrointest Endosc 2001; 53 (1): 47-52
52. Guelrud M, Herrera I, Essenfeld H et al. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001; 53 (6): 559-565
53. Guelrud M, Herrera I. Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy. Gastrointest Endosc 1998; 47 (6): 512-515
54. Endo T, Awakawa T, Takahashi H et al. Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55 (6): 641-647
55. Ferguson DD, DeVault KR, Krishna M et al. Enhanced magnification-directed biopsies do not increase the detection of intestinal metaplasia in patients with GERD. Am J Gastroenterol 2006; 101 (7): 1611-1616
56. Meining A, Rosch T, Kiesslich R et al. Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction. Endoscopy 2004; 36 (2): 160-164
57. Dickman R, Bautista JM, Wong WM et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am J Gastroenterol 2006; 101 (11): 2463-2469
58. Sharma P, McQuaid K, Dent J et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127 (1): 310-330
59. Fountoulakis A, Zafirellis KD, Dolan K et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004; 91 (8): 997-1003
60. van Sandick JW, van Lanschot JJ, Kuiken BW et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43 (2): 216-222
61. Eisen GM, Sandler RS, Murray S et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997; 92 (1): 27-31
62. Dickman R, Kim JL, Camargo L et al. Correlation of gastroesophageal reflux disease symptoms characteristics with long-segment Barrett's esophagus. Dis Esophagus 2006; 19 (5): 360-365
63. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123 (2): 461-467
64. Rex DK, Cummings OW, Shaw M et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125 (6): 1670-1677
65. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93 (7): 1028-1032
66. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997; 92 (4): 586-591
67. Falk GW, Rice TW, Goldblum JR et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999; 49 (2): 170-176
68. Heitmiller RF. Prophylactic esophagectomy in Barrett esophagus with high-grade dysplasia. Langenbecks Arch Surg 2003; 388 (2): 83-87
69. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996; 224 (1): 66-71
70. Reid BJ, Blount PL, Feng Z et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95 (11): 3089-3096
71. Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120 (7): 1630-1639
72. Rice TW. Pro: esophagectomy is the treatment of choice for high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 2006; 101 (10): 2177-2179
73. Ell C, May A, Gossner L et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118 (4): 670-677
74. May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14 (10): 1085-1091
75. May A, Gossner L, Pech O et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 2002; 34 (8): 604-610
76. Pech O, May A, Gossner L et al. Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Endoscopy 2007; 39 (1): 30-35
77. Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51 (5): 671-676
78. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120 (7): 1607-1619
79. Vieth M, Stolte M. Barrett's esophagus and neoplasia: data from the Bayreuth Barrett's archive. Gastroenterology 2002; 122 (2): 590-591
80. Seewald S, Akaraviputh T, Seitz U et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003; 57 (7): 854-859
81. May A, Gossner L, Behrens A et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003; 58 (2): 167-175
82. Kakushima N, Fujishiro M, Kodashima S et al. A learning curve for endoscopic submucosal dissection of gastric epithelial neoplasms. Endoscopy 2006; 38 (10): 991-995
83. Rosch T, Sarbia M, Schumacher B et al. Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy 2004; 36 (9): 788-801
84. Peters FP, Kara MA, Rosmolen WD et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101 (7): 1449-1457
85. Schlemper RJ, Hirata I, Dixon MF. The macroscopic classification of early neoplasia of the digestive tract. Endoscopy 2002; 34 (2): 163-168
86. Pech O, May A, Gunter E et al. The impact of endoscopic ultrasound and computed tomography on the TNM staging of early cancer in Barrett's esophagus. Am J Gastroenterol 2006; 101 (10): 2223-2229
87. Holscher AH, Bollschweiler E, Schneider PM et al. Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997; 84 (10): 1470-1473
88. Stein HJ, Feith M, Mueller J et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232 (6): 733-742
89. Rice TW, Zuccaro GJr, Adelstein DJ et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998; 65 (3): 787-792
90. Ruol A, Merigliano S, Baldan N et al. Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 1997; 10 (3): 190-195
91. van Sandick JW, van Lanschot JJ, ten Kate FJ et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer 2000; 88 (11): 2429-2437
92. Bollschweiler E, Baldus SE, Schroder W et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006; 38 (2): 149-156
93. Vieth M, Rosch T. Endoscopic mucosal resection and the risk of lymph-node metastases: indications revisited? Endoscopy 2006; 38 (2): 175-179
94. Guidelines for the clinical and pathological studies of carcinoma of the esophagus. March 1992 (8th edition): Japanese society of esophageal diseases. Tokyo: Kanehara and Co, 2003
95. Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65 (1): 3-10
96. Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62 (1): 24-30
97. Avidan B, Sonnenberg A, Schnell TG et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97 (8): 1930-1936
98. Avidan B, Sonnenberg A, Schnell TG et al. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002; 47 (2): 256-264
99. Inomata Y, Koike T, Ohara S et al. Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol 2006; 101 (5): 926-933
100. Cooper BT, Chapman W, Neumann CS et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23 (6): 727-733
101. Hillman LC, Chiragakis L, Shadbolt B et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180 (8): 387-391
102. El Serag HB, Aguirre T, Kuebeler M et al. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther 2004; 19 (12): 1255-1260
103. Jankowski JA, Perry I, Harrison RF. Gastro-oesophageal cancer: death at the junction. BMJ 2000; 321 (7259): 463-464
104. El Serag HB, Aguirre TV, Davis S et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99 (10): 1877-1883
105. Malfertheiner P, Lind T, Willich S et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005; 54 (6): 746-751
106. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117 (2): 327-335
107. Peters FT, Ganesh S, Kuipers EJ et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45 (4): 489-494
108. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98 (9): 2120-2128
109. Feagins LA, Zhang HY, Hormi-Carver K et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007; 102 (1): 10-20
110. Souza RF, Shewmake K, Terada LS et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122 (2): 299-307
111. Umansky M, Yasui W, Hallak A et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20 (55): 7987-7991
112. Anderson LA, Johnston BT, Watson RG et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia- adenocarcinoma sequence. Cancer Res 2006; 66 (9): 4975-4982
113. Corley DA, Kerlikowske K, Verma R et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124 (1): 47-56
114. Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7 (2): 97-102
115. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76 (7): 1116-1119
116. Gammon MD, Terry MB, Arber N et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13 (1): 34-39
117. Heath EI, Canto MI, Piantadosi S et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancet Inst 2007; 99 (7): 545-557
118. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 2006; 332 (7556): 1512
119. Corley DA, Levin TR, Habel LA et al. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006; 101 (5): 937-944
120. Lagergren J, Bergstrom R, Adami HO et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133 (3): 165-175
121. Vaughan TL, Farrow DC, Hansten PD et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998; 7 (9): 749-756
122. Gutschow CA, Schroder W, Prenzel K et al. Impact of antireflux surgery on Barrett's esophagus. Langenbecks Arch Surg 2002; 387 (3-4): 138-145
123. Hofstetter WL, Peters JH, DeMeester TR et al. Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001; 234 (4): 532-538
124. Ye W, Chow WH, Lagergren J et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121 (6): 1286-1293
125. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285 (18): 2331-2338
126. Lundell L, Miettinen P, Myrvold HE et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192 (2): 172-179
127. Parrilla P, Martinez de Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237 (3): 291-298